30 results about "GATA4" patented technology

Animal cells, notably adult fibroblasts, are advantageously reprogrammed in direct lineage reprogramming methods using defined factors to produce proliferative and multipotent induced cardiac progenitor cells (iCPC). The iCPC thus produced can be differentiated under suitable differentiation conditions to cardiac lineage cells including cardiomyocytes, smooth muscle cells, and endothelial cells, as evidenced by expression of lineage specific markers. Sets of factors effective in combination to reprogram the fibroblasts can include a set that includes some or all of 5 factors (Mesp1, Baf60c, Nkx2.5, Gata4, Tbx5), a set that includes some or all of 11 factors (Mesp1, Mesp2, Gata4, Gata6, Baf60c, SRF, Isl1, Nkx2.5, Irx4, Tbx5, Tbx20), a set that includes some or all of 18 factors (T, Mesp1, Mesp2, Tbx5, Tbx20, Isl1, Gata4, Gata6, Irx4, Nkx2.5, Hand1, Hand2, Tbx20, Tbx18, Tip60, Baf60c, SRF, Hey2), and a set that includes some or all of 22 factors (T, Mesp1, Mesp2, Tbx5, Tbx20, Isl1, Gata4, Gata6, Irx4, Nkx2.5, Hand1, Hand2, Tbx20, Tbx18, Tip60, Baf60c, SRF, Hey2, Oct4, Klf4, Sox2, L-myc).

The invention relates to a kit and a method for predicting a hepatocarcinogenesis risk, relating to the technical field of medical in-vitro diagnosis. Particularly, the invention relates to a kit anda method for predicting a hepatocarcinogenesis risk through the CpG island methylation states of single genes or multiple genes in SCT, NFIX, IGF2, ABCG5, GSTO2, SARDH, E2F6, SHANK2, GATA4, OPLAH, NR2F1 and ZFHX3. According to the combined methylation detection of the multiple genes, the sensitivity is greatly improved; the free nucleic acids of saliva, urine, blood and the like are detected, drawing materials from cancer tissue is not required, the detection is noninvasive, and the operation is simple and convenient.

Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3′-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.

The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.

The invention discloses an application of a TNFR2 activating agent to preparing a drug for promoting activation, migration and survival of cardiac stem cells. The TNFR2 activating agent has the effect of promoting activation of the cardiac stem cells and cardiac repair. The activated TNFR2-Bmx can enhance expression and the activity of Nkx2.5+/Gata4+, and mediate activation, migration and survival of c-Kit+ endogenous cardiac stem cells (eCSCs). In addition, the activation of the TNFR2 increases the differentiation of cardiac cells of a hESC/hiPSC source. The TNFR2 activating agent activates the TNFR2 through the specificity so that the TNFR2 is beneficial to repairing of myocardial infarction, and a new strategy can be provided for human heart disease treatment.

The invention provides a preparation method, a product and application of an alpha cell. The preparation method of the alpha cell comprises the following steps of over-expressing the following transcription factors in a somatic cell: Hhex, Foxa3, Gata4, Pdx1 and Pax4. The invention also provides the alpha cell prepared and obtained by the method and the application of the alpha cell. The invention discloses a brand-new method for obtaining the alpha cell; the alpha cell has important effects on the research and the treatment of diabetes mellitus and the application of relevant regenerative medicine; the invention also optimizes a method for preparing the alpha call; the better combination of the transcription factors is found out. The alpha cell prepared and obtained by utilizing the method provided by the invention not only has the function of a natural islet alpha cell, but also is a fungible clinical resource for treating the diabetes mellitus, which is wide in source range and is high-efficiency, stable and safe.

The invention discloses a method for inducing directional myocardiac differentiation of iPSCs (induced Pluripotent Stem Cells) with a H9C2 myocardial cell culture solution, and belongs to the technical field of medicine. The method comprises the following steps: mixing a conventional iPSCs culture solution from which LIF is removed with the H9C2 myocardial cell culture solution; culturing the iPSCs. The method proves that the H9C2 myocardial cell culture solution can effectively induce directional myocardiac differentiation of the iPSCs. Fluorescence quenching of a multi-directional differentiation potential gene OCT-4 is facilitated. As proved by a cell immunofluorescence experiment, the expression of alpha-actinin can be enhanced. As proved by a qPCR result, the expressions of mRNAs (messenger Ribonucleic Acids) such as beta-MHC, GATA4, Mef2C and NCX-1 are increased remarkably.

The invention provides a method for directly re-programming heart progenitor cells based on endogenous gene transcriptional activation. The method has better operation feasibility and theory creativity. For the first time, through a CRISPR/Cas9 system, endogenous heart development relevant transcription factors GATA4, HAND2, MEF2C, TBX5 and MEIS1 are activated, human foreskin fibroblasts are induced to be re-programmed into the heart progenitor cells having the potential of being disintegrated towards cardiac muscle cells, smooth muscle cells and endothelial cells, a seed cell source is provided for cardiovascular disease model construction, new medicine screening and myocardial regeneration, and besides, a novel apparent cell re-programming theory and connotation are enriched.

The invention relates to application of a diagnostic marker GATA4 in pancreas inflammatory cancer transformation. According to the invention, immunofluorescence detection finds that the level of the GATA4 is positively correlated with the CD68 level, and prompts that the GATA4 may participate in inflammatory regulation in the pancreatic cancer development process. According to the experiment, lipopolysaccharide (LPS) with different concentrations is added into a macrophage culture medium LMCM for inducing THP-1 differentiation to treat pancreatic cancer cells; the result shows that up-regulation of the GATA4 level in the pancreatic cancer cells can be promoted, and proliferation, migration and invasion of the pancreatic cancer cells can be promoted; and meanwhile, overexpression of the GATA4 can obviously promote proliferation, migration and invasion ability of the pancreatic cancer cells induced by the LMCM with different LPS concentrations. This prompts that the GATA4 may be a key factor in the pancreatitis cancer transformation process. The invention provides a method for diagnosing pancreas inflammatory cancer transformation through molecular detection; the diagnosis speed is high; the cost is low; and the result is accurate and reliable.

The invention discloses a method for inducing amniotic fluid mesenchymal stem cells to differentiate into cardiomyocytes in vitro. CTnI is a typical protein in ventricular and atrial cells and is an important characteristic protein of cardiomyocytes; GATA4 is an important transcriptional regulatory factor for cardiac gene expression, jointly regulates the normal development of a heart, the expression of functional genes and the pathological process of cardiac hypertrophy through interaction with other transcriptional regulatory factors, and is also an important characteristic protein of the cardiomyocytes. Through mRNA and protein expression levels of the cTnI and GATA4, the human amniotic fluid mesenchymal stem cells can be observed to be obviously differentiated into the cardiomyocytes under induction of propylgallate. Therefore, propylgallate can be used for inducing the human amniotic fluid mesenchymal stem cells to differentiate into the cardiomyocytes in vitro. The method provided by the invention can effectively induce the human amniotic fluid mesenchymal stem cells to differentiate into the cardiomyocytes.